Stopping acid-reducing pills in stable IBD
Part of Digestive system clinical trials.
This study tests whether it is safe to stop taking acid-reducing pills (PPIs) for people with inactive IBD. If you have been on a PPI for over 6 months and your IBD is stable, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 16 years old or older.
- You have been diagnosed with inflammatory bowel disease (IBD) like Crohn's or colitis.
- You have been taking a PPI (acid-reducing medicine) regularly for at least 6 months.
- Your IBD has been stable for the past 3 months (no changes in medicine or surgery).
- You do not have serious stomach conditions like Barrett's esophagus or peptic ulcers.
- You are not taking daily NSAIDs (like ibuprofen) and do not have other serious health issues listed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if older adults with ulcerative colitis who have been in remission for a long time can safely stop taking their immune-suppressing medication (thiopurine). It may help reduce medication side effects while keeping the disease under control.
This trial tests whether people with ulcerative colitis who have been in deep remission (no signs of active disease) can safely reduce or stop their current medication. It aims to find out if careful monitoring can keep them healthy without full-dose treatment.
This trial tests if patients with ulcerative colitis or Crohn's disease who are already stable on stronger medications (biologics or immunomodulators) can safely stop taking their 5-ASA (mesalamine) pill. It aims to see if stopping 5-ASA affects disease control.
This study looks at bacteria in your gut that may produce chemicals linked to ongoing pain in Crohn's disease or ulcerative colitis, even when the disease itself is not very active. Researchers want to understand why some people still have moderate to severe abdominal pain even after their inflammation has calmed down.
This study looks at people with active Crohn's disease or ulcerative colitis starting a new type of medication (anti-TNF, ustekinumab, upadacitinib, or vedolizumab), as well as people without IBD having a routine colonoscopy. It aims to collect information to better understand how these treatments work.
This study tests whether it is safe and helpful to reduce or stop daily high-dose heartburn medications (called PPIs) in patients who might not need them anymore. It is for adults who take a strong PPI every day and can communicate in German.
Hear when a new Crohn’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.